Zai Lab Limited (NASDAQ:ZLAB) reported second-quarter 2025 results that failed to meet revenue expectations, despite modest top-line growth, sending its shares down over 2% in pre-market trading.
The biopharma firm posted revenue of $110 million for the quarter, falling short of the analyst consensus of $124.95 million. However, losses narrowed significantly, with earnings per share coming in at -$0.04—well above the expected -$0.41. The company also reported a 28% year-over-year improvement in operating loss.
A standout performer for the quarter was VYVGART, which achieved record patient uptake and brought in $26.5 million in sales—a 46% increase over the previous quarter. However, ZEJULA posted lower revenues at $41 million, down from $45 million in the same quarter last year. The company attributed the decline to “evolving competitive dynamics within the PARPi class.”
“Zai Lab is entering a pivotal period – defined by innovation, scale and strong execution,” said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab. “We are making meaningful progress throughout our business – expanding patient impact, accelerating global innovation, and operating with financial discipline.”
Despite underwhelming sales results, Zai Lab reaffirmed its full-year 2025 revenue forecast of $560 million to $590 million, which remains in line with the analyst consensus of $567.7 million. The company also said it is still on track to reach profitability by Q4 2025.
On the clinical front, Zai Lab highlighted encouraging data for ZL-1310, its DLL3 antibody-drug conjugate. The treatment showed a 67% objective response rate across all dose levels in second-line small cell lung cancer patients.
The company ended the second quarter with $832.3 million in cash, cash equivalents, and short-term investments, compared to $857.3 million at the end of Q1.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.